Selling, General, and Administrative Costs: Novartis AG vs Supernus Pharmaceuticals, Inc.

A Tale of Two Pharmaceutical Giants: Novartis AG vs Supernus Pharmaceuticals, Inc.

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of major players is crucial. This chart provides a fascinating glimpse into the Selling, General, and Administrative (SG&A) expenses of Novartis AG and Supernus Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Novartis AG consistently reported SG&A expenses that were approximately 75 times higher than those of Supernus Pharmaceuticals, reflecting its expansive global operations. However, Supernus Pharmaceuticals has shown a remarkable upward trend, with its SG&A expenses increasing by over 360% from 2014 to 2023. This growth underscores Supernus's aggressive market expansion and strategic investments. Meanwhile, Novartis's expenses peaked in 2018, followed by a gradual decline, indicating a potential shift towards more efficient operations. This comparative analysis highlights the contrasting strategies and market positions of these two pharmaceutical powerhouses.